ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 787

Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus

Meenakshi Jolly1, Nisarg Gandhi2, Alana Nevares3 and Winston Sequeira2, 1Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, 2Rheumatology, Rush University Medical Center, Chicago, IL, 3Internal Medicine, Cook County Hospital, Chicago, IL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: PRO and SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Disease Specific Patient reported outcome measure tools
capture unique domains relevant to patients with a specific disease. LupusPRO
is targeted towards measuring health (HRQOL) and non-health related quality of
life (Non HRQOL) among patients with systemic lupus erythematosus (SLE).
LupusPRO V 1.7 and its translated versions in various languages have
measurement equivalence and are responsive to changes in changes in patient
reported changes in health and physician based disease activity assessments.
However, items pertaining to sleep, or impact of vitality and pain on quality
of life were placed together in the same domain (Vitality-Pain) based on factor
loadings in initial studies and in interest of parsimony. For purposes of charting
changes in individual components of this combined domain (Pain-Vitality), we
separated the sleep, pain and vitality items into separate domains, keeping
intact the concepts, content and language of the items, in version 1.8.  We
present the psychometric properties of LupusPRO v1.8, with special attention to
LupusPRO domains of sleep, vitality and pain.

Methods:

Fifty consenting SLE patients fulfilling ACR classification
criteria were given self-administered surveys (MOS SF36 FACIT-Fatigue, Pain, Insomnia
Severity Index for sleep, Perceived Stress Scale (PSS)-4, Patient Health
Questionnaire-9 (PHQ-9) for depression, LupusPRO V 1.8) to complete at routine
care visit.  Disease activity and damage were assessed at visit using SELENA-SLEDAI
(SS), numeric BILAG and SLICC-SDI/ACR (SDI). Internal consistency reliability
(ICR) for each domain was obtained using cronbach alpha. Convergent construct validity
(CV) with corresponding domains of SF36 was tested using spearman correlation
coefficient.

Results:

 Mean (SD) age was 41.4±13 yrs., 90% participants
were women. Ethnic background was as follows:  56% Blacks, 24% Whites, 10%
Asians and 10% others. Median (IQR) values of PGA, total SS, and SDI were 0.5
(0.8), 4.0(6.0) and 1.0(1.0), respectively.  Results for LupusPRO V1.8 domains
descriptives, ICR and CV are shown in Table 1. ICR for LupusPRO sleep, vitality
and pain domains exceeded 0.80.  LupusPRO Sleep domain scores inversely and
strongly correlated with the Insomnia severity index scores, while LupusPRO Vitality
(4 items) correlated strongly with FACIT-Fatigue (13 items) and SF36 Vitality
scores. LupusPRO Pain domain correlated strongly with the Pain score and SF36
Bodily pain domain.  Lupus symptom domain (3 items) showed significant
correlation with PGA, SS and BILAG.  LupusPRO domains of Physical and Emotional
Health had good ICR and significant correlation with corresponding SF36 domains
(Table 1).

Conclusion:

 LupusPRO V1.8 (including its sleep,
vitality and pain domains) has acceptable reliability and validity. It offers
significant advantages over LupusPRO V1.7 and its 36 items comprehensively
cover HRQOL in SLE.

 


Disclosure: M. Jolly, Pfizer Inc, 7; N. Gandhi, None; A. Nevares, None; W. Sequeira, None.

To cite this abstract in AMA style:

Jolly M, Gandhi N, Nevares A, Sequeira W. Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/validation-of-lupuspro-v1-8-disease-targeted-patient-reported-outcome-for-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-lupuspro-v1-8-disease-targeted-patient-reported-outcome-for-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology